Vor Biopharma Inc. (NYSE:VOR) Receives $10.92 Consensus Target Price from Analysts

Shares of Vor Biopharma Inc. (NYSE:VORGet Free Report) have been assigned a consensus recommendation of “Buy” from the six brokerages that are currently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $10.92.

Several equities analysts have recently weighed in on VOR shares. JMP Securities reiterated a “market outperform” rating and issued a $12.00 price target on shares of Vor Biopharma in a research report on Friday, September 6th. Barclays decreased their price target on Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 14th. Finally, HC Wainwright restated a “buy” rating and issued a $17.50 price objective on shares of Vor Biopharma in a research report on Friday, September 6th.

Read Our Latest Report on VOR

Institutional Trading of Vor Biopharma

Large investors have recently modified their holdings of the business. Acadian Asset Management LLC purchased a new position in Vor Biopharma in the first quarter worth $126,000. Vanguard Group Inc. increased its position in shares of Vor Biopharma by 4.0% during the 1st quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company’s stock valued at $4,297,000 after purchasing an additional 69,436 shares during the last quarter. Hsbc Holdings PLC raised its holdings in shares of Vor Biopharma by 177.0% during the 2nd quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock valued at $51,000 after buying an additional 31,333 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Vor Biopharma in the 2nd quarter worth approximately $63,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in Vor Biopharma in the second quarter worth approximately $53,000. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Stock Performance

Shares of Vor Biopharma stock opened at $0.69 on Thursday. The stock has a market capitalization of $47.11 million, a P/E ratio of -0.39 and a beta of -0.35. Vor Biopharma has a 52-week low of $0.63 and a 52-week high of $3.14. The stock’s 50-day simple moving average is $0.88 and its 200 day simple moving average is $1.28.

Vor Biopharma (NYSE:VORGet Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) EPS for the quarter, meeting analysts’ consensus estimates of ($0.41). Equities research analysts forecast that Vor Biopharma will post -1.51 EPS for the current fiscal year.

About Vor Biopharma

(Get Free Report

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.

Read More

Analyst Recommendations for Vor Biopharma (NYSE:VOR)

Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.